Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
Abstract Background The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). Methods Patients with active PsA who were biologic-naive (SPIRIT-P1) or had p...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-020-02388-5 |
id |
doaj-b16932c648be4716aed14c4aba8b6e9a |
---|---|
record_format |
Article |
spelling |
doaj-b16932c648be4716aed14c4aba8b6e9a2021-01-31T16:39:12ZengBMCArthritis Research & Therapy1478-63622021-01-0123111010.1186/s13075-020-02388-5Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe0Tsen-Fang Tsai1J. Eugene Huffstutter2Aubrey Trevelin Sprabery3Chen-Yen Lin4So Young Park5Andris Kronbergs6Matthew M. Hufford7Peter Nash8Department of Rheumatology, CHU Montpellier, Montpellier UniversityNational Taiwan UniversityArthritis AssociatesEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanySchool of Medicine, Griffith UniversityAbstract Background The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). Methods Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior inadequate response to tumor necrosis factor inhibitors (SPIRIT-P2) were randomized to 80 mg IXE every 4 (IXE Q4W) or 2 weeks (IXE Q2W), after a 160-mg initial dose. In this post hoc analysis, efficacy and safety were assessed up to week 52 in the subgroups of patients who received (i) IXE as monotherapy and (ii) IXE along with a stable dose of MTX (no dose tapering or increase). Efficacy outcomes included, but were not limited to, the percentage of patients achieving the American College of Rheumatology (ACR) responses. Results Out of 455 patients initially randomized to IXE, 177 (38.9%) received monotherapy, 230 (50.5%) had concomitant MTX use, and 48 (10.5%) had other concomitant medication. Overall, 183 (40.2%) received IXE with a stable dose of concomitant MTX for 1 year. At week 52, the percentage of patients achieving ACR20/50/70 responses in IXE Q4W monotherapy versus concomitant MTX groups were 66.3% versus 55.3%, 48.4% versus 38.8%, and 35.8% versus 27.1%, respectively; these responses were generally similar with IXE Q2W. The safety profiles were similar between patients receiving IXE with or without concomitant MTX. Conclusions In this post hoc analysis, treatment with IXE demonstrated sustained efficacy in patients with PsA up to 1 year of treatment, with or without concomitant MTX therapy. Trial registration ClinicalTrials.gov NCT01695239 and NCT02349295 .https://doi.org/10.1186/s13075-020-02388-5Psoriatic arthritisIxekizumabcDMARDsMethotrexate |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bernard Combe Tsen-Fang Tsai J. Eugene Huffstutter Aubrey Trevelin Sprabery Chen-Yen Lin So Young Park Andris Kronbergs Matthew M. Hufford Peter Nash |
spellingShingle |
Bernard Combe Tsen-Fang Tsai J. Eugene Huffstutter Aubrey Trevelin Sprabery Chen-Yen Lin So Young Park Andris Kronbergs Matthew M. Hufford Peter Nash Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies Arthritis Research & Therapy Psoriatic arthritis Ixekizumab cDMARDs Methotrexate |
author_facet |
Bernard Combe Tsen-Fang Tsai J. Eugene Huffstutter Aubrey Trevelin Sprabery Chen-Yen Lin So Young Park Andris Kronbergs Matthew M. Hufford Peter Nash |
author_sort |
Bernard Combe |
title |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies |
title_short |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies |
title_full |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies |
title_fullStr |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies |
title_full_unstemmed |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies |
title_sort |
ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of psa: week 52 results from spirit-p1 and spirit-p2 studies |
publisher |
BMC |
series |
Arthritis Research & Therapy |
issn |
1478-6362 |
publishDate |
2021-01-01 |
description |
Abstract Background The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). Methods Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior inadequate response to tumor necrosis factor inhibitors (SPIRIT-P2) were randomized to 80 mg IXE every 4 (IXE Q4W) or 2 weeks (IXE Q2W), after a 160-mg initial dose. In this post hoc analysis, efficacy and safety were assessed up to week 52 in the subgroups of patients who received (i) IXE as monotherapy and (ii) IXE along with a stable dose of MTX (no dose tapering or increase). Efficacy outcomes included, but were not limited to, the percentage of patients achieving the American College of Rheumatology (ACR) responses. Results Out of 455 patients initially randomized to IXE, 177 (38.9%) received monotherapy, 230 (50.5%) had concomitant MTX use, and 48 (10.5%) had other concomitant medication. Overall, 183 (40.2%) received IXE with a stable dose of concomitant MTX for 1 year. At week 52, the percentage of patients achieving ACR20/50/70 responses in IXE Q4W monotherapy versus concomitant MTX groups were 66.3% versus 55.3%, 48.4% versus 38.8%, and 35.8% versus 27.1%, respectively; these responses were generally similar with IXE Q2W. The safety profiles were similar between patients receiving IXE with or without concomitant MTX. Conclusions In this post hoc analysis, treatment with IXE demonstrated sustained efficacy in patients with PsA up to 1 year of treatment, with or without concomitant MTX therapy. Trial registration ClinicalTrials.gov NCT01695239 and NCT02349295 . |
topic |
Psoriatic arthritis Ixekizumab cDMARDs Methotrexate |
url |
https://doi.org/10.1186/s13075-020-02388-5 |
work_keys_str_mv |
AT bernardcombe ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT tsenfangtsai ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT jeugenehuffstutter ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT aubreytrevelinsprabery ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT chenyenlin ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT soyoungpark ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT andriskronbergs ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT matthewmhufford ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies AT peternash ixekizumabwithorwithoutconcomitantmethotrexateimprovessignsandsymptomsofpsaweek52resultsfromspiritp1andspiritp2studies |
_version_ |
1724316119669407744 |